Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072190 | 0.91 | HTT (0.46) | LMNASMN1; SMN2HPGDPOLBTP53 | |
| SCHEMBL6072351 | 0.89 | SMN1; SMN2 (0.47) | RIPK1LMNASMN1; SMN2POLBTP53 | |
| SCHEMBL6072145 | 0.88 | MET (0.47) | RIPK1LMNAPOLBTP53MET | |
| SCHEMBL6071686 | 0.86 | LMNA (0.48) | RIPK1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6072240 | 0.86 | ALDH1A1 (0.49) | LMNASMN1; SMN2HPGDPOLBTP53 | |
| SCHEMBL6072249 | 0.85 | HRH3 (0.48) | RIPK1LMNAPOLBTP53MET | |
| SCHEMBL6071666 | 0.84 | BRAF (0.53) | — | |
| SCHEMBL6072492 | 0.84 | ADRB2 (0.47) | RIPK1POLBTP53MET | |
| SCHEMBL6072163 | 0.84 | KDR (0.47) | RIPK1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6072975 | 0.83 | RAF1 (0.54) | LMNAPOLBTP53MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | ADAMS JERRY L | 2006-10-26 | — | — | US | disclosed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | CHKB, MAP3K20, MAP3K6 | RIPK1 627/4885LMNA 2570/4885UCHL1 901/4885 |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | RIPK1 3251/4885LMNA 2455/4885UCHL1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.